22 results about "ROR1" patented technology

The present invention provides ROR1 specific chimeric antigen receptors (CAR) and their therapeutic use. The CAR comprises a signal peptide, a ROR1 antigen binding domain, a hinge, a transmembrane domain, a co-stimulatory domain and an intracellular signaling domain. The modified immune cells endowed with such CARs are suitable for treating malignancies such as cancer, chronic lymphocyte leukemia (CLL), and acute lymphocytic leukemia (ALL).

This invention discloses antibodies against ROR1 or their antigen-binding fragments, kits, and their applications, relating to the fields of biotechnology and medical technology. This invention screened and obtained 10 antibodies that have high affinity for the ROR1 protein and can specifically bind to it. This allows for the development of ROR1 detection kits, tumor diagnostic and prognostic kits, as well as pharmaceutical compositions, antibody-drug conjugates, or other therapeutic methods using the aforementioned antibodies or their antigen-binding fragments. Experimental verification shows that the antibodies provided by this invention have a high killing rate against tumor cells. All of the above antibodies exhibit concentration-dependent cytotoxicity; the higher the antibody concentration, the better the anti-tumor activity. Therefore, the antibodies or their antigen-binding fragments provided by this invention show promising potential for the preparation of tumor therapeutic drugs.

The present application relates to an isolated antigen binding protein capable of binding to ROR1 (Receptor Tyrosine Kinase Orphan Receptor 1), said isolated antigen protein comprising CDR1, CDR2 and CDR3. The present application also provides a method for preparing said isolated antigen binding protein and uses thereof.

The invention relates to an antibody aiming at ROR1 and application thereof, in particular to an antibody specifically bound with ROR1 or an antigen binding fragment thereof, a nucleic acid for coding the antibody, a vector comprising the nucleic acid and a host cell comprising the nucleic acid or the vector. Compositions, kits and conjugates comprising the antibodies, as well as medical uses of the antibodies.

Provided herein are bispecific and multispecific antibodies that target tumor antigens and 4-1BB, the Fc region of which has a retained or enhanced effector function; in particular, the multispecific antibodies have binding specificity for human ROR1 protein and human 4-1BB protein. Also provided herein are methods of treating cancer using the antibodies or fragments thereof.

Provided are bispecific antibodies targeting ROR1 and CD3 and uses thereof, the bispecific antibodies comprising a first antigen-binding moiety and a second antigen-binding moiety wherein the first antigen-binding moiety is an antibody or antigen-binding fragment thereof that specifically binds to ROR1 and the second antigen-binding moiety is an antibody or antigen-binding fragment thereof that specifically binds to CD3.

Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging / diagnostic agents.

This invention discloses a peroxisome-targeting chimeric compound, PexTAC, and its applications, belonging to the field of target protein degradation technology. The invention provides a peroxisome-targeting chimeric compound, PexTAC, with the general structural formula A-L-B, where A is the peroxisome-targeting module, L is the linker, and B is the target protein recognition module. PexTAC recruits target proteins to the peroxisome membrane and utilizes the endogenous E3 ubiquitin ligase SYVN1 for specific degradation via the proteasome pathway. This platform can not only target ROR1 to inhibit tumor growth but also induce ferroptosis through the bispecific PexTAC synergistic degradation of HSPA5 and GPX4. This invention overcomes the dependence of traditional PROTAC technology on limited E3 ligases, providing a novel modular degradation strategy for targeting "undruggable" proteins and organelle-related proteins.

The present disclosure provides anti-tyrosine protein kinase membrane receptor 1 antibody-drug conjugate structures. The antibody-drug conjugate structure comprises branched linkers, wherein each branched linker links two or more payloads to an antibody. In addition, the present disclosure also encompasses compounds and methods for producing such conjugates. In addition, the present disclosure also encompasses methods of using the conjugates.

Provided herein are methods and compositions for the treatment of cancer, such methods comprising the combined use of a ROR1 antagonist and a checkpoint inhibitor antagonist.

The invention relates to an antibody capable of specifically recognizing ROR1 as well as a preparation method and application of the antibody. The present application also relates to antibody-conjugated drugs (ADCs) targeting ROR1 and compositions containing the molecules. In addition, the invention also relates to therapeutic and diagnostic uses of these antibodies, antibody fragments and antibody-conjugated drugs.

The present specification provides a single domain antibody that targets the ROR1 protein, and a chimeric antigen receptor (CAR) and CAR-T cells comprising the single domain antibody. The present specification further provides applications of the single domain antibody and CAR-T cells in the treatment of tumors that express the ROR1 protein.

The present invention provides antibodies targeting ROR1, as well as multispecific antibodies, chimeric antigen receptors, antibody conjugates, pharmaceutical compositions and kits comprising the same, and their use in the diagnosis / treatment / prevention of diseases associated with ROR1 expression.

The invention provides an anti-ROR1 nano antibody and an application thereof. Through alpaca immunization and a phage library, a high-affinity nano antibody HCAbs1 is screened out, and through flow cytometry and a pull-down experiment, it is determined that the HCAbs1 can be effectively combined with ROR1. The HBABs1 can reduce the ERK phosphorylation level stimulated by Wnt5a in ROR1 stably transfected cells, and has huge potential in the aspects of cancer diagnosis and treatment.

The invention discloses a polypeptide targeting ROR1 protein, a long-acting small-molecule conjugate of the polypeptide and application of the long-acting small-molecule conjugate. The polypeptide disclosed by the invention is selected from any one of the following three fragments: RH1, RH2 and RH3 or a combination of a plurality of fragments, the composition of the RH1 fragment is X1INSG, the composition of the RH2 fragment is X2SDINDX3X4IX5, and the composition of the RH3 fragment is GYSTYX6GDFX7. According to the present invention, the ROR1 protein targeting polypeptide or the ROR1 protein targeting derivative is adopted as the targeting carrier, is further coupled with the toxin micromolecule and other drugs, and is subjected to long-acting modification, such that the high targeting property, the high permeability and the high action time on the ROR1 positive solid tumor can be provided through the advantages, the high specificity and the high targeting property of the various drugs can be achieved, and the application prospect is broad. Therefore, a better diagnosis or treatment effect is achieved.

The present application relates to an isolated antigen binding protein capable of binding to ROR1 (Receptor Tyrosine Kinase Orphan Receptor 1), said isolated antigen protein comprising CDR1, CDR2 and CDR3. The present application also provides a method for preparing said isolated antigen binding protein and uses thereof.

Provided are bispecific and multi-specific antibodies that target a tumor antigen and 4-1BB with a Fc region maintained or improved with effector function, particular multi-specific antibodies having binding specificity to the human ROR1 protein and human 4-1BB protein. Methods of using the antibodies or fragments thereof for treating cancer are also provided.

The application discloses an antibody against ROR1 and application thereof, and relates to the technical fields of biotechnology and medicine. Ten antibodies are screened and obtained, the antibodies have high affinity to ROR1 protein, and can specifically combine with the ROR1 protein, so that an ROR1 detection kit containing the antibodies, a tumor diagnosis kit, a prognosis kit, a pharmaceutical composition, an antibody-drug conjugate and other treatment methods using the antibodies can be developed. It is verified through experiments that the antibody has high killing rate on tumor cells, and the higher the antibody concentration is, the better the anti-tumor activity is. Therefore, the antibody or the antigen binding fragment thereof has good prospects for preparing an anti-tumor drug.